Citations

Mayo Clinic

Showing 10 of 108599 citations.

Management of Recurrent and Metastatic HPV‐Positive Oropharyngeal Squamous Cell Carcinoma after Transoral Robotic Surgery
Sims, John R. , Abel, Kathryn M. Van , Martin, Eliot J., Lohse, Christine M. , Olsen, Kerry D., Moore, Eric J. , Van Abel, Kathryn, Price, Daniel L. , Van Abel, Kathryn M

Otolaryngology–Head and Neck Surgery | April 4, 2017 | Volume: 157 | Issue: 1 | Pages: 69-76

10.1177/0194599817696304 | PMID 28374634 Get It

ObjectiveTo describe management and oncologic outcomes for patients who develop locoregional recurrence (LRR) or distant metastasis (DM) following transoral robotic surgery for human papilloma virus (HPV)–positive oropharyngeal squamous cell carcinoma (OPSCC).Study DesignCase series with chart review.SettingTertiary care referral center.Subjects and MethodsA total of 286 patients with HPV‐positive OPSCC who underwent transoral robotic surgery–based treatment from May 2007 to May 2015.ResultsOf 286 patients (12.2%), 35 met inclusion criteria. Of these, 19 experienced an LRR and 16 developed a DM; 2 patients with LRR subsequently developed DM. In those patients with an LRR, 79% had T1/T2 tumors, and 47% had N0/N1 nodal disease, compared with 75% and 6% in the DM group, respectively. The median time to LRR or DM was 0.6 years (interquartile range [IQR], 0.4‐1.0) and 1.8 years (IQR, 1.0‐2.1), respectively. Salvage treatment with intent to cure was attempted in 23 patients (16 LRR, 7 DM). The median time from LRR or DM to last follow‐up for the 18 patients who were still alive after salvage was 1.9 years (IQR, 0.4‐3.8; range, 7 days–6.2 years). Estimated cancer‐specific survival rates at 3 years following intent‐to‐cure treatment were 63% (95% CI, 39‐100; number still at risk, 5) in the LRR group and 100% (95% CI, 100‐100; number still at risk, 2) in the DM group.ConclusionOverall, LRR and DM for HPV‐positive OPSCC following transoral robotic surgery–based therapy are infrequent. In our subset of patients who underwent intent‐to‐cure treatment, cancer‐specific survival rates were favorable. Therefore, aggressive salvage treatment for LRR and DM for HPV‐positive OPSCC should be recommended for appropriate candidates.
A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: Introduction
Shriberg, Lawrence D., Fourakis, Marios, Jakielski, Kathy J., Hall, Sheryl D., Karlsson, Heather B., Mabie, Heather L. , McSweeny, Jane L., Tilkens, Christie M., Strand, Edythe A. , Wilson, David L.

Journal of Speech, Language, and Hearing Research | April 3, 2017 | Volume: 60 | Issue: 4 | Pages: No page available

10.1044/2016_jslhr-s-16-0148 | PMID 28384695 Get It

Purpose The goal of this article is to introduce the pause marker (PM), a single-sign diagnostic marker proposed to discriminate early or persistent childhood apraxia of speech (CAS) from speech delay.
Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms
Goel, Swati , Pereira, Arturo , Efficace, Fabio , Barbui, Tiziano , Tefferi, Ayalew , Cervantes, Francisco , Cervantes, Francisco , Paoli, Chiara , Iurlo, Alessandra , Vannucchi, Alessandro M. , Efficace, Fabio

European Journal of Haematology | April 3, 2017 | Volume: 99 | Issue: 1 | Pages: 36-41

10.1111/ejh.12887 | PMID 28370510 Get It

AbstractObjectiveTo determine the financial and psycho‐social impact of participation in clinical trials of patients with BCR/ABL‐negative myeloproliferative neoplasms (MPN).MethodsAn international, observational cross‐sectional study was performed in 143 consecutive MPN patients (51% myelofibrosis, 36% polycythemia vera, 13% essential thrombocythemia), 68% from Italy, 17% from USA, and 15% from Spain.ResultsThirty‐five percent of patients reported having spent more money during the trial than in previous treatments and 21% having missed more workdays. Twelve percent replied that they would not have participated in the trial if the financial consequences would have been known beforehand. In 10% of the patients, the interpersonal relationships were more affected during the trial than in previous treatment but, overall, 91% subjects believed that participating in the clinical trial was worth the financial or emotional suffering. Concerning patients’ suggestions, 54% of them indicated that the number of visits required for the trial should be clearly specified in the informed consent, 60% recommended travel cost reimbursement, and 23% hotel cost reimbursement.ConclusionsPhysicians and pharmaceutical companies involved in clinical trials with patients with hematological diseases should be aware of these problems and make efforts to attenuate the socioeconomic burden of participation in the trials.
Abstract B21: The selective ATR inhibitor VX-970 enhances the therapeutic effects of standards of care in glioblastoma
Burgenske, Danielle M. , Mladek, Ann C. , Sarkaria, Jann N.

Molecular Cancer Research | April 3, 2017 | Volume: 15 | Issue: 4_Supplement | Pages: B21-B21

10.1158/1557-3125.dnarepair16-b21 Get It

Abstract Glioblastoma (GBM) represents one of the most aggressive cancer types with the vast majority of patients succumbing to disease within the first five years. This dire prognosis reflects the limited efficacy of our frontline therapies which include radiation therapy and temozolomide (TMZ) chemotherapy. The cellular response to these therapies is critically mediated by DNA damage response signaling networks that are regulated by Ataxia Telangiectasia Mutated (ATM) and Ataxia Telangiectasia And Rad3-Related Protein (ATR). Preliminary studies from our laboratory suggest the ATR inhibitor VX-970 has single agent efficacy in both established and primary GBM cell lines. Moreover, combined treatment with TMZ demonstrated therapeutic responses that, following regression analysis, were deemed synergistic (p<0.001). Validation studies using siRNA confirmed ATR as a central mediator of TMZ sensitivity as knockdown of ATM elicited no added benefit when tested in combination. VX-970 also enhanced radiation effects in neurosphere formation assays to suggest it may also be used as a radiosensitizer. While the specific mechanism responsible for these observations has yet to be determined, VX-970 treatment was found to exert anti-proliferative effects in a dose-dependent manner. This collection of work suggests that ATR inhibition may represent a worthwhile treatment strategy in GBM. Citation Format: Danielle Burgenske, Ann Mladek, Jann Sarkaria. The selective ATR inhibitor VX-970 enhances the therapeutic effects of standards of care in glioblastoma [abstract]. In: Proceedings of the AACR Special Conference on DNA Repair: Tumor Development and Therapeutic Response; 2016 Nov 2-5; Montreal, QC, Canada. Philadelphia (PA): AACR; Mol Cancer Res 2017;15(4_Suppl):Abstract nr B21.
Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy
Cooper, Leslie T. , Givertz, Michael M. , Alexis, Jeffrey D. , Felker, G. Michael , Chaparro, Sandra , Kealey, Angela, Pisarcik, Jessica, Fett, James D., McNamara, Dennis M. , Investigators, the Investigations of Pregnancy Associated Cardiomyopathy (IPAC), Schelbert, Erik B. , Elkayam, Uri , Briller, Joan Ellen , Investigators, the Investigations of Pregnancy Associated Cardiomyopathy (IPAC), Cooper, Leslie T

Journal of the American Heart Association | April 3, 2017 | Volume: 6 | Issue: 4 | Pages: No page available

10.1161/jaha.117.005472 | PMID 28373243 Get It

Background In peripartum cardiomyopathy, the prevalence of focal myocardial damage detected by late gadolinium enhancement ( LGE ) cardiovascular magnetic resonance is important to elucidate mechanisms of myocardial injury and cardiac dysfunction. LGE equates irreversible myocardial injury, but LGE prevalence in peripartum cardiomyopathy is uncertain. Methods and Results Among 100 women enrolled within the Investigations of Pregnancy Associated Cardiomyopathy cohort, we recruited 40 women at 13 centers to undergo LGE cardiovascular magnetic resonance, enrolled within the first 13 weeks postpartum. Follow‐up scans occurred at 6 months postpartum, and death/transplant rates at 12 months. Baseline characteristics did not differ significantly in the parent cohort according to cardiovascular magnetic resonance enrollment except for mechanical circulatory support. LGE was noted only in 2 women (5%) at baseline. While left ventricular dysfunction with enlargement was prevalent at baseline cardiovascular magnetic resonance scans (eg, ejection fraction 38% [Q1–Q3 31–50%], end diastolic volume index=108 mL/m 2 [Q1–Q3 83–134 mL/m 2 ]), most women demonstrated significant improvements at 6 months, consistent with a low prevalence of LGE . LGE was not related to baseline clinical variables, ejection fraction, New York Heart Association heart failure class, or mortality. Neither of the 2 women who died exhibited LGE . LGE was inversely associated with persistent left ventricular ejection fraction at 6 months ( P =0.006). Conclusions Factors other than focal myocardial damage detectable by LGE explain the initial transient depressions in baseline left ventricular ejection fraction, yet focal myocardial damage may contribute to persistent myocardial dysfunction and hinder recovery in a small minority. Most women exhibit favorable changes in ventricular function over 6 months. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01085955.
Heparin‐bridging therapy and risk of post‐polypectomy bleeding: Meta‐analysis of data reported by Japanese colonoscopists
Jaruvongvanich, Veeravich , Assavapongpaiboon, Buravej , Wijarnpreecha, Karn , Ungprasert, Patompong , Wijarnpreecha, Karn

Digestive Endoscopy | April 3, 2017 | Volume: 29 | Issue: 7 | Pages: 743-748

10.1111/den.12882 | PMID 28370508 Get It

Background and Aim Peri‐procedural bridging ( PPB ) with heparin is recommended for patients with high thromboembolic risk who need to withhold antithrombotic therapy for colonoscopic polypectomy. However, little is known about the bleeding risk from heparin‐bridging therapy itself. Methods MEDLINE and EMBASE databases were searched through January 2017 for studies that compared the risk of PPB in patients who received heparin‐bridging therapy in lieu of antithrombotic agents for colonoscopic polypectomy and those who discontinued antithrombotic agents without receiving heparin. Pooled odds ratio ( OR ) and 95% confidence interval ( CI ) were calculated using a random‐effects model, generic inverse variance method. Between‐study heterogeneity was quantified using the Q statistic and I 2 . Results A total of five studies consisting of 2601 patients were identified. A significantly increased risk of PPB among bridged patients compared to non‐bridged patients was demonstrated with a pooled OR of 8.29 (95% CI , 4.96–13.87). Statistical heterogeneity was low with I 2 of 0%. Conclusion The present study demonstrated a significantly increased risk of PPB among patients who underwent colonoscopic polypectomy and received heparin‐bridging therapy in lieu of antithrombotic agents compared to patients who did not receive it.
Endovascular Embolization by Transcatheter Delivery of Particles: Past, Present, and Future
Sheth, Rahul A. , Sabir, Sharjeel , Avery, Reginald K. , Khademhosseini, Ali, Öklü, Rahmi , Krishnamurthy, Savitri , Zhang, Yu Shrike , Oklu, Rahmi

Journal of Functional Biomaterials | April 3, 2017 | Volume: 8 | Issue: 2 | Pages: 12

10.3390/jfb8020012 | PMID 28368345 Get It

Minimally invasive techniques to occlude flow within blood vessels, initially pioneered in the 1970s with autologous materials and subsequently advanced with increasingly sophisticated engineered biomaterials, are routinely performed for a variety of medical conditions. Contemporary interventional radiologists have at their disposal a wide armamentarium of occlusive agents to treat a range of disease processes through a small incision in the skin. In this review, we provide a historical perspective on endovascular embolization tools, summarize the current state-of-the-art, and highlight burgeoning technologies that promise to advance the field in the near future.
Oral rehydration therapy training and clinical simulation experience to improve students’ confidence in preparation for international medical mission trip to Nicaragua
Oliver, Jeremie D. , Bachman, John W., Bachman, John, Oliver, Jeremie D

Journal of European CME | April 3, 2017 | Volume: 6 | Issue: 1 | Pages: 1310419

10.1080/21614083.2017.1310419 | PMID 29644129 Get It

Judicial oversight of life-ending withdrawal of assisted nutrition and hydration in disorders of consciousness in the United Kingdom: A matter of life and death
Rady, Mohamed Y, Verheijde, Joseph L., Rady, Mohamed Y

Medico-Legal Journal | April 3, 2017 | Volume: 85 | Issue: 3 | Pages: 148-154

10.1177/0025817217702289 | PMID 28368210 Get It

Mr Justice Baker delivered the Oxford Shrieval Lecture ‘A Matter of Life and Death’ on 11 October 2016. The lecture created public controversies about who can authorise withdrawal of assisted nutrition and hydration (ANH) in disorders of consciousness (DOC). The law requires court permission in ‘best interests’ decisions before ANH withdrawal only in permanent vegetative state and minimally conscious state. Some clinicians favour abandoning the need for court approval on the basis that clinicians are already empowered to withdraw ANH in other common conditions of DOC (e.g. coma, neurological disorders, etc.) based on their best interests assessment without court oversight. We set out a rationale in support of court oversight of best interests decisions in ANH withdrawal intended to end life in any person with DOC (who will lack relevant decision-making capacity). This ensures the safety of the general public and the protection of vulnerable disabled persons in society.
Posterolateral Rotatory Instability of the Elbow: Part I. Mechanism of Injury and the Posterolateral Rotatory Drawer Test
Smith, Jay , O’Driscoll, Shawn W. , O'Driscoll, Shawn W., Camp, Christopher L. , Fitzsimmons, James S

Arthroscopy Techniques | April 3, 2017 | Volume: 6 | Issue: 2 | Pages: No page available

10.1016/j.eats.2016.10.016 | PMID 28580259 Get It

Abstract Posterolateral rotatory instability (PLRI) is the most commonly encountered pattern of elbow instability. It is the result of disruption of the lateral collateral ligament complex leading to a posterolateral rotatory subluxation of the ulna and radial head. A number of examination maneuvers have been described to assist in clinical identification of PLRI. Despite this, some inconsistency in the description of these techniques remains in the orthopaedic literature. This Technical Note details the mechanism of injury and patient presentation, and emphasizes the primacy of the posterolateral rotatory drawer test in the assessment of PLRI while providing video instruction on how it should be performed. Technique Video video See video under supplementary data.